Commentary on Enns Et Al. (2016): Supervised Injection Facilities As a Cost-effective Intervention

Overview

Journal Addiction

Specialty Psychiatry

Date 2016 Feb 11

PMID 26860246

Authors

Nadia Fairbairn

Evan Wood

Affiliations

Soon will be listed here.

References

Strathdee S, Ricketts E, Huettner S, Cornelius L, Bishai D, Havens J . Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2005; 83(3):225-32. PMC: 2196224. DOI: 10.1016/j.drugalcdep.2005.11.015. View

Wood E, Tyndall M, Zhang R, Stoltz J, Lai C, Montaner J . Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med. 2006; 354(23):2512-4. DOI: 10.1056/NEJMc052939. View

Strathdee S, Hallett T, Bobrova N, Rhodes T, Booth R, Abdool R . HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010; 376(9737):268-84. PMC: 6464374. DOI: 10.1016/S0140-6736(10)60743-X. View

Andresen M, Boyd N . A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility. Int J Drug Policy. 2009; 21(1):70-6. DOI: 10.1016/j.drugpo.2009.03.004. View

Wood E, Tyndall M, Zhang R, Montaner J, Kerr T . Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction. 2007; 102(6):916-9. DOI: 10.1111/j.1360-0443.2007.01818.x. View

Milloy M, Wood E . Emerging role of supervised injecting facilities in human immunodeficiency virus prevention. Addiction. 2009; 104(4):620-1. DOI: 10.1111/j.1360-0443.2009.02541.x. View

Pinkerton S . How many HIV infections are prevented by Vancouver Canada's supervised injection facility?. Int J Drug Policy. 2011; 22(3):179-83. DOI: 10.1016/j.drugpo.2011.03.003. View

Marshall B, Milloy M, Wood E, Montaner J, Kerr T . Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011; 377(9775):1429-37. DOI: 10.1016/S0140-6736(10)62353-7. View

Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R . Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011; (8):CD004145. DOI: 10.1002/14651858.CD004145.pub4. View

10.

Wood E, Kerr T, Small W, Li K, Marsh D, Montaner J . Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ. 2004; 171(7):731-4. PMC: 517857. DOI: 10.1503/cmaj.1040774. View

11.

Pinkerton S . Is Vancouver Canada's supervised injection facility cost-saving?. Addiction. 2010; 105(8):1429-36. DOI: 10.1111/j.1360-0443.2010.02977.x. View

12.

Enns E, Zaric G, Strike C, Jairam J, Kolla G, Bayoumi A . Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada. Addiction. 2015; 111(3):475-89. DOI: 10.1111/add.13195. View

13.

Degenhardt L, Whiteford H, Ferrari A, Baxter A, Charlson F, Hall W . Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382(9904):1564-74. DOI: 10.1016/S0140-6736(13)61530-5. View

14.

Bayoumi A, Zaric G . The cost-effectiveness of Vancouver's supervised injection facility. CMAJ. 2008; 179(11):1143-51. PMC: 2582765. DOI: 10.1503/cmaj.080808. View

15.

Nolan S, Dias Lima V, Fairbairn N, Kerr T, Montaner J, Grebely J . The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction. 2014; 109(12):2053-9. PMC: 4229435. DOI: 10.1111/add.12682. View